Limitless Potential.
Precision Design.
Enduring Impact.
Aiming to transform cancer care by developing curative allogeneic cell therapies
PRESS RELEASES + EVENTS
view all
16-May-2022
Century Therapeutics Reports First Quarter 2022 Financial Results and Provides Business Updates
– Phase 1 ELiPSE-1 trial of CNTY-101 in relapsed/refractory lymphoma expected to commence in the…
03-May-2022
Century Therapeutics to Present at Upcoming Investor Conferences
PHILADELPHIA, May 03, 2022 (GLOBE NEWSWIRE) — Century Therapeutics (NASDAQ: IPSC), an innovative biotechnology company…
About us
We are building a fully integrated biotechnology company that is developing transformational next generation iPSC-derived iNK and iT cell therapies for hematological and solid tumor malignancies.
OUR SCIENCE
We are leveraging the unlimited self-renewing capacity of induced pluripotent stem cells (iPSC) and cutting-edge cellular engineering and manufacturing technologies to develop fit-for-purpose products with functionalities designed to overcome the limitations of existing cell therapies.
